<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fernando C Fervenza, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjeev Sethi, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven Flamm, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark H Wener, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H170076869">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cryoglobulins are classified into three types [
         <a href="#rid1">
          1
         </a>
         ]. Type I cryoglobulins are composed of one monoclonal immunoglobulin (Ig; typically IgG or IgM) and are commonly seen in the setting of a lymphoproliferative disease. By contrast, mixed cryoglobulinemia syndrome (MCS) refers to the presence of either type II or type III cryoglobulins circulating in the serum, composed of polyclonal IgG bound to another immunoglobulin with rheumatoid factor activity. In type II cryoglobulinemia, this immunoglobulin with rheumatoid factor activity is monoclonal (usually IgM isotype), whereas in type III cryoglobulinemia, it is polyclonal. Types II and III cryoglobulins account for up to 90 percent of all cryoglobulinemia cases [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         MCS can manifest clinically as a systemic vasculitis with manifestations ranging from purpura, arthralgia, and weakness to more severe neurologic and kidney involvement. Until recently, the most common cause of MCS was hepatitis C virus (HCV), but the introduction of direct-acting antiviral agents has significantly reduced the incidence of HCV-associated cryoglobulinemia [
         <a href="#rid3">
          3
         </a>
         ]. Other infections, lymphoproliferative, and autoimmune disorders have also been associated with the disease.
        </p>
        <p>
         The etiology, clinical manifestations, and diagnosis of MCS will be reviewed here. The treatment of this disorder and an overview of cryoglobulins and cryoglobulinemia are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2984100850">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryoglobulinemia
         </strong>
         – Cryoglobulinemia refers to the presence of cryoglobulin in a patient's serum. This term is sometimes used interchangeably with cryoglobulinemic vasculitis (or cryoglobulinemia syndrome).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed cryoglobulinemia
         </strong>
         – Mixed cryoglobulinemia refers to cryoglobulins in the serum that contain more than one immunoglobulin component (for example, immunoglobulin M [IgM] rheumatoid factor [RF] and polyclonal immunoglobulin G [IgG]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed cryoglobulinemia
         </strong>
         <strong>
          syndrome
         </strong>
         – Mixed cryoglobulinemia syndrome (MCS) refers to a systemic inflammatory syndrome that generally involves small-to-medium vessel vasculitis due to cryoglobulin-containing immune complexes. This term is generally used to distinguish the asymptomatic presence of cryoglobulins from the clinically apparent disorder with end-organ damage. MCS can be caused by either type II or type III cryoglobulins, the characteristics of which are described below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Essential mixed cryoglobulinemia
         </strong>
         – Essential mixed cryoglobulinemia was the traditional term for what was thought to be idiopathic vasculitis caused by circulating cryoglobulins that contain both a polyclonal IgG and an IgM RF directed against the IgG, which are called mixed cryoglobulins. It was later discovered that in most patients, this disorder is associated with chronic hepatitis C virus (HCV) infection. Therefore, this term currently refers to the very small percentage of patients with MCS in the absence of underlying disease.
        </p>
        <p>
        </p>
        <p>
         Other related terms are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Terminology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H285322008">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common cause of mixed cryoglobulinemia syndrome (MCS) is chronic hepatitis C virus (HCV) infection. Other causes include chronic hepatitis B virus (HBV) infection, HIV infection, autoimmune diseases, and hematologic disorders  (
         <a class="graphic graphic_table graphicRef52034" href="/z/d/graphic/52034.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1796875995">
         <span class="h2">
          Idiopathic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally patients have MCS with no known etiology or association with other disorders.
        </p>
        <p class="headingAnchor" id="H290252956">
         <span class="h2">
          Infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of infections have been associated with MCS. In addition to HCV, HBV, and HIV infection, a variety of other viruses and bacterial, fungal, and parasitic infections have also been described in association with MCS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HCV infection
         </strong>
         – Chronic HCV infection is the most common cause of MCS, accounting for 80 to 90 percent of cases [
         <a href="#rid5">
          5-9
         </a>
         ]. However, the prevalence of HCV infections varies according to geographical regions. As an example, in some parts of northern Europe, such as the Netherlands, there is a very low prevalence of HCV infection and HCV is not found in patients with MCS [
         <a href="#rid10">
          10
         </a>
         ] Although hepatomegaly and chronic liver disease are common in these patients, some do not have elevated serum aminotransferase levels [
         <a href="#rid8">
          8
         </a>
         ]. Thus, there may be little or no clinical evidence of active hepatitis at the time of presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most HCV-infected patients who have circulating mixed cryoglobulins do
         <strong>
          not
         </strong>
         develop vasculitis. In a study of 226 patients with chronic liver disease, 127 had HCV infection [
         <a href="#rid11">
          11
         </a>
         ], and 69 HCV-infected patients (54 percent) had circulating cryoglobulins, frequently with anti-HCV antibodies and HCV RNA concentrated in the cryoprecipitates. The prevalence of circulating cryoglobulins was higher with increasing apparent duration of disease (9.8 versus 5.3 years) and the presence of cirrhosis. Only 18 (26 percent) of the patients with circulating cryoglobulins had clinical symptoms compatible with MCS. In another study that included 139 patients with HCV-related chronic liver disease and circulating cryoglobulins, approximately one-half had clinical symptoms of MCS [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HBV infection
         </strong>
         – MCS is associated with HBV infection in up to 5 percent of cases [
         <a href="#rid13">
          13
         </a>
         ]. In the series of 226 patients with chronic liver disease described in the preceding section, chronic HBV infection was present in 40 patients; circulating cryoglobulins were present in 15 percent (compared with 4 percent in controls) [
         <a href="#rid11">
          11
         </a>
         ]. HBV-associated cryoglobulinemic vasculitis has also been described in other studies [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         – Some cases of MCS are due to HIV infection. This relationship was illustrated in a series of 89 HIV-1-infected patients from Greece, among whom mixed cryoglobulins were detected in 24 (27 percent) [
         <a href="#rid16">
          16
         </a>
         ]. Antibodies to HIV-1 were detected in all of the cryoprecipitates, and HIV-1 RNA sequences were detected in all but one of the cryoprecipitates. Nine of these patients had symptoms compatible with MCS (eg, palpable purpura, arthralgias, and mononeuritis multiplex). Only 6 of the 24 patients with circulating cryoglobulins were infected with HCV, and only three of these patients had HCV RNA sequences in the cryoprecipitate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2441949947">
         <span class="h2">
          Autoimmune diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         MCS has been observed in approximately 10 percent of patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis [
         <a href="#rid17">
          17
         </a>
         ]. Approximately 5 to 20 percent of patients with primary Sjögren's disease may have type II cryoglobulinemia [
         <a href="#rid18">
          18
         </a>
         ]; in such patients, this finding has been associated with extraglandular involvement, the development of systemic vasculitis, B cell lymphoma, and poor survival [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1117952477">
         <span class="h2">
          Lymphoproliferative disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mixed cryoglobulinemia can occur in patients with non-Hodgkin lymphoma, although cryoglobulinemia occurring with lymphoma is usually type I (ie, associated with cryoglobulins containing only a single monoclonal immunoglobulin component). In a study of 81 patients with biopsy-proven non-hepatitis-associated cryoglobulinemic glomerulonephritis (56 percent with type II, 29 percent with type I, and 8 percent with type III cryoglobulins), an underlying hematologic condition was found in 89 percent (including 100 percent of patients with type I and 91 percent of patients with type II cryoglobulinemia). Of the patients with a hematologic condition, 35 percent had a symptomatic lymphoproliferative disorder and 65 percent had monoclonal gammopathy of renal significance [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Etiopathogenesis'
         </a>
         .)
        </p>
        <p>
         A separate issue is the association between MCS and the development of non-Hodgkin lymphoma. In one study of 1255 HCV-infected patients with MCS, the overall risk of non-Hodgkin lymphoma was approximately 35 times higher than in the general population or 12 times higher if nonaggressive lymphomas were excluded [
         <a href="#rid21">
          21
         </a>
         ]. Independent factors associated with the development of B cell non-Hodgkin lymphoma include serum cryoglobulin levels &gt;0.6 g/L, the presence of cryoglobulinemic vasculitis, and hypogammaglobulinemia [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H876509753">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of mixed cryoglobulinemia syndrome (MCS) is mediated by the deposition of antigen-antibody complexes in capillaries and small arterioles, and occasionally also in small arteries. The pathogenesis of MCS is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Etiopathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H718788108">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H914364960">
         <span class="h2">
          Overview of typical findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major clinical manifestations of mixed cryoglobulinemia syndrome (MCS) include palpable purpura (which is a major finding suggesting some form of small vessel vasculitis)  (
         <a class="graphic graphic_picture graphicRef78697" href="/z/d/graphic/78697.html" rel="external">
          picture 1
         </a>
         ), kidney disease, arthralgias or arthritis, nonspecific systemic symptoms including weakness, peripheral neuropathy, and hypocomplementemia (with the fall in C4 levels often being most prominent) [
         <a href="#rid7">
          7,9,23-26
         </a>
         ]. Patients may present with various combinations of these features, and different manifestations may predominate at different times in an individual patient.
        </p>
        <p>
         A review of 231 patients with MCS followed in an Italian rheumatology clinic reported the following clinical findings at presentation and during follow-up [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common clinical features at presentation were purpura (81 percent, with skin ulcers in 11 percent), weakness and fatigue (80 percent), arthralgia (72 percent), and frank arthritis (8 percent) [
         <a href="#rid26">
          26
         </a>
         ]. The clinical triad of purpura, weakness, and arthralgia ("Meltzer's triad") was present early in the course in almost 80 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral neuropathy was present in 58 percent, typically with a mild peripheral sensorimotor pattern. A minority of these patients progressed to more severe neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney involvement was present in 20 percent and eventually developed in 30 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild to moderate liver involvement was present in 58 percent and eventually developed in 77 percent, including some patients who advanced to cirrhosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Raynaud phenomenon was present in 36 percent, and sicca symptoms were present in 29 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory testing revealed type II cryoglobulinemia in 62 percent and type III cryoglobulinemia in 38 percent. Rheumatoid factor [RF] was found in all patients, and most had hypocomplementemia, typically with very low C4 levels. Evidence of hepatitis C virus (HCV) infection was found in 92 percent of patients, and hepatitis B virus (HBV) DNA was detected in only 1.8 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical features were similar in patients with type II and type III mixed cryoglobulinemia syndrome, except for more frequent sicca symptoms in the latter group.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H72561850">
         <span class="h2">
          Specific organ involvement
         </span>
        </p>
        <p class="headingAnchor" id="H2959827523">
         <span class="h3">
          Cutaneous involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous manifestations develop in nearly all patients with MCS [
         <a href="#rid1">
          1,9,24,27,28
         </a>
         ] and may precede extracutaneous manifestations by decades. Typically, these lesions consist of erythematous macules and purpuric papules of the lower extremities (90 to 95 percent)  (
         <a class="graphic graphic_picture graphicRef51770" href="/z/d/graphic/51770.html" rel="external">
          picture 2
         </a>
         ), though infarction, hemorrhagic crusts, and ulcers also occur (10 to 25 percent). Postinflammatory hyperpigmentation (30 to 50 percent) and exacerbation as a result of cold exposure (10 to 30 percent) are common. Morphologic abnormalities of the nailfold vasculature, including tortuosity and apical enlargement, are seen on capillaroscopy [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H855235515">
         <span class="h3">
          Musculoskeletal involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Musculoskeletal complaints such as arthralgias and myalgias are common in patients with MCS, but frank arthritis or myositis is rare [
         <a href="#rid13">
          13,30,31
         </a>
         ]. Arthralgias are typically described in over 70 percent of patients, especially affecting the metacarpophalangeal and proximal phalangeal joints, knees, and ankles, often in type III cryoglobulinemia and often exacerbated by cold exposure.
        </p>
        <p class="headingAnchor" id="H2011714170">
         <span class="h3">
          Peripheral nerve involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuropathy affects a high percentage of patients with MCS. Electromyographic and nerve conduction studies have demonstrated the presence of peripheral neuropathy in over 70 to 80 percent of patients with mixed cryoglobulins [
         <a href="#rid32">
          32-34
         </a>
         ], but many symptom-based demographic studies report prevalences of only 30 to 45 percent. Severe peripheral neuropathy, such as mononeuropathy multiplex or combined sensorimotor disease, is uncommon [
         <a href="#rid35">
          35-37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">
          "Clinical manifestations and diagnosis of vasculitic neuropathies", section on 'Patterns of nerve involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3571912360">
         <span class="h3">
          Kidney involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence of kidney disease, typically membranoproliferative glomerulonephritis, is apparent at presentation in approximately 20 percent of patients with MCS, with an additional 10 to 30 percent developing kidney disease during follow-up [
         <a href="#rid9">
          9,25,26,38-40
         </a>
         ]. On average, kidney disease is detected approximately 2.5 years after disease onset [
         <a href="#rid25">
          25
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">
          "Overview of kidney disease associated with hepatitis C virus infection"
         </a>
         ). It is most common in the setting of type II cryoglobulinemia [
         <a href="#rid13">
          13
         </a>
         ]. On the other hand, glomerular involvement occurs in less than 10 percent of cases of type III cryoglobulinemia [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         The clinical presentation of the kidney disease is variable. The following kidney presentations were noted in a review of 146 patients with HCV-related MCS with glomerulonephritis [
         <a href="#rid25">
          25
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microscopic hematuria and subnephrotic proteinuria with or without chronic kidney disease – 41 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nephrotic syndrome with or without chronic kidney disease – 22 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute glomerulonephritis – 14 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic kidney disease without significant urinalysis abnormalities – 13 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute kidney injury – 9 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension (which can be severe) – approximately 65 percent
        </p>
        <p>
        </p>
        <p>
         The kidney presentations were similar in patients with type II and type III MCS.
        </p>
        <p>
         The presence of kidney disease is a major factor in determining the long-term prognosis of patients with MCS. Risk factors for progression of the kidney disease are similar to those noted in other forms of glomerular disease: an elevated serum creatinine, higher rates of proteinuria, and older age [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4077059792">
         <span class="h3">
          Pulmonary involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subclinical pulmonary manifestations appear to be common in MCS [
         <a href="#rid42">
          42-44
         </a>
         ]. Pulmonary function tests often reveal evidence of small airways disease and impairment of gas exchange, with symptoms in approximately 10 to 20 percent of patients, usually ranging from dyspnea to cough and pleurisy. Organizing pneumonia, alveolar hemorrhage, and pulmonary vasculitis have been reported but appear to be very uncommon.
        </p>
        <p class="headingAnchor" id="H286401571">
         <span class="h2">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other manifestations have been reported with varying frequency, such as lymphadenopathy in up to 20 percent, splenomegaly in up to 30 percent, and abdominal pain in up to 20 percent (which sometimes reflects active mesenteric vasculitis) [
         <a href="#rid31">
          31,45
         </a>
         ]. Manifestations such as hepatomegaly, abnormal liver function tests, or abnormal liver biopsy in up to 90 percent are not related to the cryoglobulinemia but to the main cause (eg, HCV infection). Clinically significant vasculitis of most other internal organs, such as of the heart, central nervous system, and retinal vessels, rarely complicates MCS. However, pathologic findings suggest that more widespread, though subclinical, involvement may be more frequent.
        </p>
        <p>
         Some patients with MCS share a number of symptoms common to patients with sicca syndrome and primary Sjögren's disease, such as dry mouth, dry eyes, arthralgia, purpura, positive RF, and cryoglobulins. However, only a few would fulfill criteria for diagnosis of primary Sjögren's disease [
         <a href="#rid4">
          4,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4090087284">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of mixed cryoglobulinemia syndrome (MCS) is typically made from the history, typical manifestations of the disease (such as purpura, arthralgias, weakness), and the laboratory detection of serum cryoglobulins. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3403160287">
         <span class="h2">
          When to suspect MCS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of MCS should be suspected in any patient who presents with one or more of the following clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Palpable purpura
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin ulcers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arthralgias and/or arthritis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral neuropathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microscopic hematuria or proteinuria with or without chronic kidney disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated serum rheumatoid factor level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low serum C4 complement level
        </p>
        <p>
        </p>
        <p>
         The index of suspicion for MCS should be raised further if these occur in the setting of viral infection (eg, hepatitis C virus [HCV], hepatitis B virus [HBV], or HIV), connective tissue disease (eg, systemic lupus erythematosus [SLE], Sjögren's disease, or rheumatoid arthritis), monoclonal gammopathy, or lymphoproliferative disorder (eg, non-Hodgkin lymphoma). (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2897546580">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients suspected of having MCS (see
         <a class="local">
          'When to suspect MCS'
         </a>
         above), the initial evaluation should include a thorough history and physical examination and laboratory testing to assess for associated diseases as well as other possible comorbidities.
        </p>
        <p class="headingAnchor" id="H1779822316">
         <span class="h3">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         A history and physical examination should be performed in all patients, with an assessment of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         – Patients should be questioned about the presence of constitutional symptoms (eg, fever, fatigue, weakness, weight loss), arthralgias, or myalgias. Some patients develop purpura or skin ulcerations, exacerbated by cold temperature. The presence of acute foot or wrist drop may suggest a motor neuropathy from an ischemic process. Patients should also be asked about the presence of concomitant infection, particularly with HCV, HBV, and HIV. Symptoms of other systemic rheumatic diseases, particularly SLE and systemic sclerosis (SSc), that may identify an overlap syndrome should be sought, and patients should be queried about cutaneous eruptions, photosensitivity, and Raynaud phenomenon. Patients should also be queried regarding prior or concomitant monoclonal gammopathy or hematologic malignancy (eg, non-Hodgkin lymphoma).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – Characteristic skin findings such as purpura, livedo reticularis, skin necrosis, or ulcers should be identified. A general physical exam should include blood pressure measurement and a neurologic and neuromuscular exam to assess for motor weakness, such as foot drop or wrist drop. Lower extremity edema may be suggestive of kidney involvement. Abnormal nailfold capillaroscopy may be suggestive of a concomitant connective tissue disease in patients who have Raynaud phenomenon. (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Nailfold capillary microscopy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4217596992">
         <span class="h3">
          Laboratory evaluation
         </span>
        </p>
        <p class="headingAnchor" id="H335040120">
         <span class="h4">
          Testing for cryoglobulins
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients suspected of having MCS should undergo laboratory testing to detect the presence of serum cryoglobulins. The method used to test for and quantify cryoglobulins is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Detection of cryoglobulins'
         </a>
         .)
        </p>
        <p>
         Summarized briefly, 10 to 20 mL of blood are drawn into syringes or collection tubes that have been
         <strong>
          prewarmed to 37°C without anticoagulants
         </strong>
         since anticoagulants can produce false-positive results due to cryofibrinogen or heparin-precipitable complexes. False negative results can be seen if this protocol is not followed. In cases in which cryoglobulinemia is suspected but initial results are negative, consideration should be given to drawing a new specimen that is kept warm and handled by the clinical laboratory to prevent cryoprecipitation.
        </p>
        <p>
         Among patients with mixed cryoglobulinemia, the cryocrit (the percentage of packed cryoglobulins compared with total serum volume after centrifugation at 4°C) is generally between 2 and 7 percent in type II, between 1 and 3 percent in type III, and much higher in type I  (
         <a class="graphic graphic_picture graphicRef82774" href="/z/d/graphic/82774.html" rel="external">
          picture 3
         </a>
         ). The cryocrit in individuals without cryoglobulinemia is close to zero, and a cryocrit over 0.5 to 1 percent or cryoglobulin concentration above 2 to 5 mg/dL is considered clinically significant [
         <a href="#rid24">
          24,47,48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Classification'
         </a>
         .)
        </p>
        <p>
         If serum cryoglobulins are detected, the immunoglobulin components of the cryoprecipitate can be identified and classified by immunoelectrophoresis or immunofixation, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Immunochemical analysis'
         </a>
         .)
        </p>
        <p>
         There is a poor correlation between the cryocrit and clinical manifestations of MCS. In addition, many patients with chronic HCV infection have mixed cryoglobulinemia
         <strong>
          without
         </strong>
         the clinical syndrome of mixed cryoglobulinemia. This was illustrated in a study of 1083 unselected patients with chronic HCV infection in which 40 percent had low concentrations of serum cryoglobulins, which were type II in 65 percent and type III in 35 percent [
         <a href="#rid49">
          49
         </a>
         ]. Among the patients with cryoglobulinemia, only 2.1 percent had vasculitis and 2.5 percent had purpura.
        </p>
        <p>
         As many as 30 to 40 percent of the patients with type II and occasional patients with type III mixed cryoglobulinemia do
         <strong>
          not
         </strong>
         have detectable circulating cryoglobulins at presentation [
         <a href="#rid39">
          39
         </a>
         ]. This may be due, in part, to simple technical errors or, more frequently, to the high variability of serum levels of cryoprecipitable immune complexes between patients and within the same patient during clinical follow-up [
         <a href="#rid50">
          50
         </a>
         ]. Thus, in patients with overt MCS who do not have detectable serum mixed cryoglobulins, periodic testing for cryoglobulins may be advisable. In addition, some patients who present with kidney disease do not have detectable cryoglobulins or common manifestations of MCS [
         <a href="#rid20">
          20,39,40
         </a>
         ]. Laboratory tests that suggest the presence of a cryoglobulin are a positive rheumatoid factor (RF; present in approximately two-thirds of patients) together with hypocomplementemia with low C4 levels (and normal or mildly decreased C3 levels), particularly in patients with membranoproliferative glomerulonephritis on kidney biopsy. (See
         <a class="local">
          'Additional laboratory testing'
         </a>
         below.)
        </p>
        <p>
         In some patients, immune deposits with ultrastructural features compatible with cryoglobulins can be detected on biopsy of affected tissue, such as the kidney or skin [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="local">
          'Tissue biopsy in selected patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1948963735">
         <span class="h4">
          Additional laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to testing for cryoglobulins, the following laboratory tests should be performed in all patients suspected of having MCS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum creatinine level and urinalysis with urine sediment
         </strong>
         – A serum creatinine and urinalysis with urine sediment may help identify the presence of kidney involvement and the degree of injury if present. Patients with evidence of abnormal kidney function, microscopic hematuria, proteinuria, or an active urinary sediment may need further evaluation with a kidney biopsy. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood count
         </strong>
         – Patients with MCS may have a temperature-dependent increase in the apparent leukocyte and platelet counts when blood samples are tested at temperatures of 30°C or less. This can result in white blood cell counts as high as 50,000/microL and a doubling of the platelet count, both of which are attributed to various sizes of precipitated cryoglobulin particles, which may be counted as white blood cells and/or platelets in automated cell counters [
         <a href="#rid51">
          51,52
         </a>
         ]. This effect is increased if the sample is allowed to cool to lower temperatures and disappears if the sample is kept at body temperature. However, many hematology instruments do not allow temperature-controlled analyses. (See
         <a class="medical medical_review" href="/z/d/html/6682.html" rel="external">
          "Approach to the patient with thrombocytosis", section on 'Blood smear'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver function tests
         </strong>
         – Serum aminotransferase activity, bilirubin, and albumin may help determine if underlying liver disease is present, particularly among patients with evidence of HCV or HBV infection. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests for HCV, HBV, and HIV
         </strong>
         – Possible infection with HCV, HBV, and HIV infection should be investigated in
         <strong>
          all
         </strong>
         patients with suspected MCS given the etiologic relationship described above. (See
         <a class="local">
          'Infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HCV RNA has been found in the liver and in peripheral blood mononuclear cells of patients with chronic liver disease in the absence of both HCV RNA and anti-HCV antibodies in the serum [
         <a href="#rid53">
          53
         </a>
         ]. Rarely, whole blood or the cryoprecipitate may test positive for HCV when routinely handled serum does not because of removal of virtually all of the HCV virion from serum or plasma into the cryoprecipitate or cellular phase of blood.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Issues related to testing for these infections are discussed in detail elsewhere:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">
          "Screening and diagnosis of chronic hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">
          "Screening and diagnostic testing for HIV infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatoid factor
         </strong>
         – RF is usually present, often at high levels, in sera of patients with type II and type III mixed cryoglobulinemia. (See
         <a class="medical medical_review" href="/z/d/html/1824.html" rel="external">
          "Rheumatoid factor: Biology and utility of measurement"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum complement levels
         </strong>
         – Serum C4 levels are consistently and often markedly low; C3 and CH50 are frequently decreased to a lesser extent [
         <a href="#rid9">
          9,54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">
          "Overview and clinical assessment of the complement system", section on 'Complement measurement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoantibodies
         </strong>
         – Testing for other autoantibodies should include an antinuclear antibody (ANA) test and, if positive, anti-double-stranded DNA (anti-dsDNA), anti-Sm, anti-Ro/SSA, anti-La/SSB, and anti-U1 ribonucleoprotein (RNP) antibodies. In addition, an antineutrophil cytoplasmic antibody (ANCA) test (anti-myeloperoxidase [anti-MPO] and anti-proteinase 3 [anti-PR3]) should be performed to distinguish MCS from ANCA-associated vasculitis. (See
         <a class="medical medical_review" href="/z/d/html/1822.html" rel="external">
          "Measurement and clinical significance of antinuclear antibodies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monoclonal protein studies
         </strong>
         – Testing for the presence of a monoclonal gammopathy should include a serum protein electrophoresis (SPEP) with immunofixation and a serum free light chain assay. Serum matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) is a more sensitive technique and allows for identification of a monoclonal IgG in cases with negative immunofixation [
         <a href="#rid55">
          55
         </a>
         ]. Detection of a monoclonal protein is suggestive of a diagnosis of type I, whereas presence of a small monoclonal component can be seen in type II. Monoclonal gammopathy is rarely associated with type III cryoglobulinemia. (See
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1392687339">
         <span class="h3">
          Tissue biopsy in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the diagnosis can generally be made based on clinical and laboratory data, biopsies of affected organs can help provide histopathologic evidence of cryoglobulinemic vasculitis in cases of diagnostic uncertainty. Mixed cryoglobulinemia syndromes (types II and III) predominantly involve the skin, kidney, and peripheral nervous system. The histopathologic findings on biopsies of affected organs are described below. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Biopsy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin
         </strong>
         – Skin lesions in MCS most often reveal leukocytoclastic vasculitis (50 percent), less commonly inflammatory or noninflammatory purpura (10 to 20 percent)  (
         <a class="graphic graphic_picture graphicRef54126" href="/z/d/graphic/54126.html" rel="external">
          picture 4
         </a>
         ), noninflammatory hyaline thrombosis (10 percent), or postinflammatory sequelae (10 percent). Direct immunofluorescence microscopy of acute lesions often reveals deposits of IgM, IgG, and/or C3 complement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral nerve
         </strong>
         – Peripheral nerve lesions in MCS typically demonstrate vasculitis, generally of the epineurial vessels [
         <a href="#rid35">
          35,56-59
         </a>
         ]. Necrotizing vasculitis or demyelination may be present, with occasional deposits of immunoglobulin and/or complement [
         <a href="#rid60">
          60
         </a>
         ]. Pauci-inflammatory occlusive lesions are sometimes seen as well, suggesting a primary role for neuronal ischemia in disease pathogenesis, and are more suggestive of type I cryoglobulinemia. Affected nerves often display axonal degeneration, likely secondary to disease of the vasa vasorum. Most studies have focused upon histopathology of sural nerve biopsies, which are presumed to reflect systemic neuronal damage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney
         </strong>
         – Histologic examination of the kidney reveals a membranoproliferative glomerulonephritis in over 80 percent of patients, with both thickening of the glomerular basement membrane and cellular proliferation  (
         <a class="graphic graphic_picture graphicRef71702" href="/z/d/graphic/71702.html" rel="external">
          picture 5
         </a>
         ) usually with abundant intracapillary infiltration of monocytes and macrophages far greater than seen in other forms of proliferative glomerulonephritis [
         <a href="#rid23">
          23
         </a>
         ]. In the remaining cases, kidney biopsy will usually show an endocapillary proliferative glomerulonephritis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Three other histologic findings are more specific for cryoglobulin-induced disease [
         <a href="#rid61">
          61
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intraluminal thrombi ("immune thrombi") composed of precipitated cryoglobulins on light microscopy  (
         <a class="graphic graphic_picture graphicRef50680" href="/z/d/graphic/50680.html" rel="external">
          picture 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diffuse dominant IgM (or codominant immunoglobulin) deposition in the capillary loops on immunofluorescence microscopy  (
         <a class="graphic graphic_picture graphicRef60046" href="/z/d/graphic/60046.html" rel="external">
          picture 7
         </a>
         ). C3 deposition is present in &gt;80 percent of the cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Subendothelial deposits on electron microscopy  (
         <a class="graphic graphic_picture graphicRef69200" href="/z/d/graphic/69200.html" rel="external">
          picture 8
         </a>
         ) that often have a clear substructure consisting of cylinders or short microtubules measuring 10 to 25 nm in thickness, with a characteristic "comma-like" or "fingerprint" (type III cryoglobulinemia) pattern of cryoprecipitates  (
         <a class="graphic graphic_picture graphicRef81450" href="/z/d/graphic/81450.html" rel="external">
          picture 9
         </a>
         ). Less commonly described substructures include bundles of microtubules with cross- or patch-hatched configuration (type I cryoglobulinemia) and fibrillar deposits. Subepithelial deposits are uncommon since the cryoglobulins are too large to pass through the glomerular basement membrane and enter the subepithelial space.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H832101406">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no established criteria for the diagnosis of MCS. The diagnosis of MCS is typically made based upon the presence of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Demonstration of an elevated cryocrit, such as greater than 0.5 to 1 percent, or a cryoglobulin concentration greater than 5 mg/dL. (See
         <a class="local">
          'Testing for cryoglobulins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of characteristic clinical features, such as palpable purpura or skin ulcers, arthralgias or arthritis, peripheral neuropathy, and evidence of kidney involvement,
         <strong>
          and
         </strong>
         a low serum C4 concentration. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Direct histologic and immunochemical evidence of cryoglobulins from pathologic specimens may provide additional evidence for the diagnosis but are not always observed or required for diagnostic purposes. As an example, tissue biopsies and histologic confirmation of the presence of cryoglobulins is not part of the classification criteria for MCS proposed by the Italian study group on cryoglobulinemia [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Some patients may present with nonspecific symptoms, such as weakness or arthralgias, in the presence of a serum cryoglobulin. In such cases, evidence of a low C4 serum level or a frequently associated disorder, such as HCV infection or a clinically evident systemic disease (eg, Sjögren's disease) increases the likelihood of MCS.
        </p>
        <p class="headingAnchor" id="H3677446829">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with suspected mixed cryoglobulinemia syndrome (MCS) may present with clinical features that overlap with a number of other autoimmune and neoplastic disorders [
         <a href="#rid4">
          4,50,63
         </a>
         ]. While it is beyond the scope of this review to provide a comprehensive list of all possible alternative diagnoses, we present several here:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other vasculitides
         </strong>
         – Other vasculitides that affect small- or medium-sized vessels may have overlapping features with MCS. These include drug-induced small vessel vasculitis (hypersensitivity vasculitis), IgA vasculitis (IgAV; Henoch-Schönlein purpura), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (eg, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis [Churg-Strauss syndrome]), and infection-related vasculitis (eg, bacterial endocarditis, poststreptococcal vasculitis, and glomerulonephritis). Vasculitis associated with a connective tissue disorder (eg, systemic lupus erythematosus [SLE], rheumatoid arthritis, Sjögren's disease) may or may not be mediated by cryoglobulins. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults", section on 'Clinical features suggestive of systemic vasculitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sjögren's disease
         </strong>
         – Patients with primary Sjögren's disease may share many of the same clinical features as found in MCS, including dryness of the eyes and mouth, arthralgias, purpura, a positive serum rheumatoid factor (RF), positive serum testing for mixed cryoglobulins, and an increased risk for developing B cell lymphoma. Primary Sjögren's disease can be differentiated from MCS by the presence of specific histopathologic changes in the salivary glands and positive testing for anti-Ro/SSA and/or anti-La/SSB autoantibodies, which are rarely present in patients with MCS. Conversely, most patients with MCS have chronic hepatitis C virus (HCV) infection and a low serum C4 level, which are uncommon in patients with primary Sjögren's disease. Distinguishing between these disorders may be more difficult in patients who are HCV negative and present with symptoms common to both Sjögren's disease and MCS; such patients are thought to have an MCS-primary Sjögren's disease overlap syndrome [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatoid arthritis
         </strong>
         – In general, patients with MCS usually have a mild, nonerosive arthritis. However, some patients with HCV-associated MCS may develop an erosive, symmetrical polyarthritis that resembles that seen in patients with rheumatoid arthritis. RF testing may be positive in both MCS and rheumatoid arthritis and is therefore not useful in distinguishing these disorders. In such cases, anticyclic citrullinated peptide antibody testing, which is positive in rheumatoid arthritis but negative in MCS, may be helpful. (See
         <a class="medical medical_review" href="/z/d/html/7503.html" rel="external">
          "Biologic markers in the assessment of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2042013628">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">
          "Society guideline links: Glomerular disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3320290655">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Mixed cryoglobulinemia syndrome (MCS) refers to the presence of either type II or type III cryoglobulins circulating in the serum, which can manifest clinically as a systemic vasculitis with manifestations ranging from purpura, arthralgia, and weakness to more severe neurologic and kidney involvement. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – The most common cause of MCS is chronic hepatitis C virus (HCV) infection. Other causes include chronic hepatitis B (HBV) infection, HIV infection, autoimmune diseases, and hematologic disorders  (
         <a class="graphic graphic_table graphicRef52034" href="/z/d/graphic/52034.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The pathogenesis of MCS is mediated by the deposition of antigen-antibody complexes in capillaries and small arterioles, and occasionally also in small arteries. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Etiopathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The major clinical manifestations of MCS include palpable purpura (which is a major finding suggesting some form of small vessel vasculitis)  (
         <a class="graphic graphic_picture graphicRef78697" href="/z/d/graphic/78697.html" rel="external">
          picture 1
         </a>
         ), kidney disease, arthralgias or arthritis, nonspecific systemic symptoms including weakness, peripheral neuropathy, and hypocomplementemia (with the fall in C4 levels often being most prominent). Patients may present with various combinations of these features, and different manifestations may predominate at different times in an individual patient. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          When to suspect MCS
         </strong>
         – The diagnosis of MCS should be suspected in any patient who presents with one or more of the following clinical features: palpable purpura, skin ulcers, arthralgias and/or arthritis, peripheral neuropathy, and/or microscopic hematuria or proteinuria with or without chronic kidney disease. The index of suspicion for MCS should be raised further if these occur in the setting of viral infection (eg, HCV, HBV, or HIV), connective tissue disease (eg, systemic lupus erythematosus [SLE], Sjögren's disease, or rheumatoid arthritis), or lymphoproliferative disorder (eg, non-Hodgkin lymphoma). (See
         <a class="local">
          'When to suspect MCS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Establishing the diagnosis
         </strong>
         – There are no established criteria for the diagnosis of MCS. The diagnosis of MCS is typically made based upon the presence of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Demonstration of an elevated cryocrit, such as greater than 0.5 to 1 percent, or a cryoglobulin concentration greater than 5 mg/dL.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Presence of characteristic clinical features, such as palpable purpura or skin ulcers, arthralgias or arthritis, peripheral neuropathy, and evidence of kidney involvement,
         <strong>
          and
         </strong>
         a low serum C4 concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Direct histologic and immunochemical evidence of cryoglobulins from pathologic specimens may provide additional evidence for the diagnosis but are not always observed or required for diagnostic purposes. Some patients may present with nonspecific symptoms, such as weakness or arthralgias, in the presence of serum mixed cryoglobulins. In such cases, evidence of a low C4 serum level or a frequently associated disorder, such as HCV infection or a clinically evident systemic disease (eg, Sjögren's disease) increases the likelihood of MCS. (See
         <a class="local">
          'Establishing the diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1310753436">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert A Kyle, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolopp-Sarda MN, Nombel A, Miossec P. Cryoglobulins Today: Detection and Immunologic Characteristics of 1,675 Positive Samples From 13,439 Patients Obtained Over Six Years. Arthritis Rheumatol 2019; 71:1904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cacoub P, Saadoun D. Extrahepatic Manifestations of Chronic HCV Infection. N Engl J Med 2021; 384:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol 2015; 7:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991; 9:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84:3047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tervaert JW, Van Paassen P, Damoiseaux J. Type II cryoglobulinemia is not associated with hepatitis C infection: the Dutch experience. Ann N Y Acad Sci 2007; 1107:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adinolfi LE, Utili R, Attanasio V, et al. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol 1996; 28:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nat Rev Dis Primers 2018; 4:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawakami T, Ooka S, Mizoguchi M, et al. Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir. Ann Intern Med 2008; 149:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enomoto M, Nakanishi T, Ishii M, et al. Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med 2008; 149:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimitrakopoulos AN, Kordossis T, Hatzakis A, Moutsopoulos HM. Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1. Ann Intern Med 1999; 130:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001; 30:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzioufas AG, Manoussakis MN, Costello R, et al. Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjögren's syndrome. Arthritis Rheum 1986; 29:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers 2016; 2:16047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaugue V, Valeri AM, Jaffer Sathick I, et al. The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. Kidney Int 2022; 102:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005; 165:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007; 46:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico G, Colasanti G, Ferrario F, Sinico RA. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989; 35:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen SJ, Pittelkow MR, Su WP. Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. J Am Acad Dermatol 1991; 25:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giuggioli D, Manfredi A, Lumetti F, et al. Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature. Semin Arthritis Rheum 2015; 44:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Mansouri M, Baldovino S, et al. Nail fold videocapillaroscopy in mixed cryoglobulinaemia. Nephrol Dial Transplant 2004; 19:2245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberger A, Berliner S, Pinkhas J. Articular manifestations of essential cryoglobulinemia. Semin Arthritis Rheum 1981; 10:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dammacco F, Lauletta G, Russi S, et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med 2019; 19:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, La Civita L, Cirafisi C, et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 1992; 19:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gemignani F, Pavesi G, Fiocchi A, et al. Peripheral neuropathy in essential mixed cryoglobulinaemia. J Neurol Neurosurg Psychiatry 1992; 55:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gemignani F, Melli G, Inglese C, Marbini A. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst 2002; 7:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Bragado F, Fernandez JM, Navarro C, et al. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 1988; 45:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stricker RB, Sanders KA, Owen WF, et al. Mononeuritis multiplex associated with cryoglobulinemia in HIV infection. Neurology 1992; 42:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stricker RB, Kiprov DD. Mononeuritis and cryoglobulins. Neurology 1993; 43:2159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012; 119:5996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viegi G, Fornai E, Ferri C, et al. Lung function in essential mixed cryoglobulinemia: a short-term follow-up. Clin Rheumatol 1989; 8:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bombardieri S, Paoletti P, Ferri C, et al. Lung involvement in essential mixed cryoglobulinemia. Am J Med 1979; 66:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertorelli G, Pesci A, Manganelli P, et al. Subclinical pulmonary involvement in essential mixed cryoglobulinemia assessed by bronchoalveolar lavage. Chest 1991; 100:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montagnino G. Reappraisal of the clinical expression of mixed cryoglobulinemia. Springer Semin Immunopathol 1988; 10:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis 1998; 57:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Della Rossa A, Tavoni A, D'Ascanio A, et al. Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol 2010; 39:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002; 55:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zandecki M, Dupriez B, Fenaux P, et al. Cytological and ultrastructural assessment of free crystals or precipitates associated with pseudoleukocytosis and pseudothrombocytosis in cryoglobulinemia. Nouv Rev Fr Hematol 1989; 31:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson CV, Stelfox P, Rees-Unwin KS. Needle-like cryoglobulin crystals presenting as spurious thrombocytosis. Br J Haematol 2006; 135:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaghloul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 2010; 39:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarantino A, Anelli A, Costantino A, et al. Serum complement pattern in essential mixed cryoglobulinaemia. Clin Exp Immunol 1978; 32:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clin Chem 2016; 62:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chad D, Pariser K, Bradley WG, et al. The pathogenesis of cryoglobulinemic neuropathy. Neurology 1982; 32:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tredici G, Petruccioli MG, Cavaletti G, et al. Sural nerve bioptic findings in essential cryoglobulinemic patients with and without peripheral neuropathy. Clin Neuropathol 1992; 11:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonetti B, Invernizzi F, Rizzuto N, et al. T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy. J Neuroimmunol 1997; 73:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavaletti G, Petruccioli MG, Crespi V, et al. A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 1990; 53:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadoun D, Terrier B, Semoun O, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) 2011; 63:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinico RA, Winearls CG, Sabadini E, et al. Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis. Kidney Int 1988; 34:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quartuccio L, Isola M, Corazza L, et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford) 2014; 53:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, Ramos-Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev 2016; 15:1145.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3062 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4216269" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Biologic and clinical significance of cryoglobulins. A report of 86 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31136095" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cryoglobulins Today: Detection and Immunologic Characteristics of 1,675 Positive Samples From 13,439 Patients Obtained Over Six Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33730456" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Extrahepatic Manifestations of Chronic HCV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25848462" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1662567" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Association between hepatitis C virus and mixed cryoglobulinemia [see comment].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1383822" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A role for hepatitis C virus infection in type II cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7949176" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1326246" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7704562" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17804553" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Type II cryoglobulinemia is not associated with hepatitis C infection: the Dutch experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7513667" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8743066" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30072738" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075217" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075218" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10049201" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11303309" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3489468" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27383445" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35513122" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15642884" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17566058" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2651764" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Renal involvement in essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6996482" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17185147" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15190522" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1880249" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25547031" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15238627" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Nail fold videocapillaroscopy in mixed cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7233245" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Articular manifestations of essential cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30430284" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1328632" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1311372" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Peripheral neuropathy in essential mixed cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11939353" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2847694" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Peripheral neuropathy in essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1436518" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mononeuritis multiplex associated with cryoglobulinemia in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8414001" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mononeuritis and cryoglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723249" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7853784" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Renal manifestations of hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678440" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22474249" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2805608" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Lung function in essential mixed cryoglobulinemia: a short-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/443251" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lung involvement in essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1935328" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Subclinical pulmonary involvement in essential mixed cryoglobulinemia assessed by bronchoalveolar lavage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3046019" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Reappraisal of the clinical expression of mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27789466" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9536813" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cryoglobulins are not essential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20337547" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524695" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11825916" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cryoglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2616269" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cytological and ultrastructural assessment of free crystals or precipitates associated with pseudoleukocytosis and pseudothrombocytosis in cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16889616" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Needle-like cryoglobulin crystals presenting as spurious thrombocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20380524" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/668194" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Serum complement pattern in essential mixed cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27540026" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6283424" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The pathogenesis of cryoglobulinemic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1319290" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sural nerve bioptic findings in essential cryoglobulinemic patients with and without peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058770" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2176233" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20981809" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Hepatitis C virus-associated polyarteritis nodosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3050245" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24994905" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Validation of the classification criteria for cryoglobulinaemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27640316" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
